Onconetix, the Cincinnati-based public company that until recently marketed oncology diagnostics, is trying a dramatic reinvention. The Nasdaq-listed firm plans to buy Las Vegas-based Realbotix LLC and recast itself as an AI-driven humanoid-robotics company, shifting its focus from cancer tests to customer-facing robots.
Deal details
As reported by Cincinnati Business Courier, Onconetix (Nasdaq: ONCO) has agreed to acquire Realbotix LLC in an all-stock transaction. The companies said they are not disclosing a cash purchase price.
Terms and conditions
In a Form 8-K filed with the SEC, Onconetix said the share exchange is structured so that Realbotix’s parent would own between 75% and 90% of the combined company’s fully diluted shares, with the exact percentage tied to Onconetix’s net cash at closing.
The filing states that the transaction is conditioned on customary approvals, including stockholder votes, required U.S. and Canadian securities clearances, and the conversion or amendment of certain outstanding convertible securities. The companies said the deal is expected to close in the second half of 2026, subject to those conditions.
Why Realbotix
Company statements describe Realbotix as a developer of lifelike, AI-powered humanoids designed for healthcare, hospitality and retail, with demonstrations at CES 2026 and early enterprise trials with partners such as Ericsson.
Andrew J. Oakley, Onconetix’s board chair, said the combination “will significantly enhance shareholder value,” while Realbotix CEO Andrew Kiguel highlighted the firm’s vision and interaction capabilities in a press release.
Local impact and risks
Onconetix is headquartered in the PNC Center at 201 E. Fifth St. downtown, and the transaction would convert a small Cincinnati-listed biotech into a U.S.-manufacturing robotics operator.
Market summaries and analysts have warned that the mechanics of the share exchange could be highly dilutive and depend on lining up substantial new capital, concerns drawn from the companies’ own disclosures and filings.
What's next
Both companies said Onconetix will file a Registration Statement on Form S-4 and that stockholder approval will be required before the exchange can close, according to company communications. Realbotix has scheduled an investor call for Feb. 13 to discuss the transaction and the status of its 2025 audit, and the parties said they expect the combined company to trade on Nasdaq once the regulatory steps are completed.
